Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Infectious Diseases: Pathogenesis and Therapy

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1597782

Respiratory infections in the post-COVID-19 era: Impact, prevalence, and clinical characteristics of bacterial and viral co-infections

Provisionally accepted
  • 1National Laboratory “Influenza and ARD”, Department of Virology, National Centre of Infectious and Parasitic Diseases, Sofia, Bulgaria
  • 2Medical University Sofia, Sofia, Sofia City, Bulgaria

The final, formatted version of the article will be published soon.

Introduction: Humans are affected by respiratory infections globally, originating from both bacterial and viral agents. However, the pathogens responsible for respiratory tract infections and the specific effects of viral-viral, viral-bacterial, and bacterial-bacterial co-infections on disease progression and clinical outcomes remain unclear. Тhis study aimed to determine the prevalence, estimate the age burden, and provide clinical characteristics of mono-and co-infections involving various bacterial and viral co-pathogens. Methods: A total of 609 nasopharyngeal specimens were collected from outpatients and hospitalized patients with respiratory symptoms between April and December 2024. The specimens were analyzed using an in-house multiplex real-time polymerase chain reaction method. Six separate primer and probe mixtures were prepared to detect 15 respiratory viruses and 5 common bacterial respiratory pathogens. Results: This study, conducted over an 8-month period, found that 65.7% of the patients (400) had at least one respiratory pathogen, with viral infections (49.2%) being more common than bacterial infections (16.5%). Infections were categorized as follows: Viral mono-infections: 217 cases (35.6%); Bacterial-bacterial co-infections: 6 cases (1%); Viral-viral co-infections: 39 cases (6.4%); and Bacterial-viral co-infections: 87 cases (34.3%). Common pathogens causing mono-and co-infections included SARS-CoV-2, rhinovirus, influenza A/B, bocavirus, adenovirus, Streptococcus pneumoniae, and Streptococcus pyogenes. Mixed infections were more common in children aged <5 years (p<0.05). The disease resulted in a fatal outcome in four patients (1.3%). Notably, one patient with confirmed Streptococcus pneumoniae serotype 11A/D had a fatal outcome. Analysis of age as a factor in infection severity revealed that infants aged 7–11 months and patients aged >65 years with bacterial-viral co-infections had mean saturations of 89.6 ± 10.4% and 90 ± 5%, respectively. Moreover, hospitalized patients aged >65 with viral-viral co-infections exhibited significantly higher C-reactive protein levels (150.8 ± 14.3 mg/L) compared to children aged < 15 (p<0.05). Conclusion: This study identified SARS-CoV-2, rhinoviruses, adenoviruses, and Streptococcus pneumoniae as key respiratory pathogens associated with mono-and co-infections. Mixed infections with SARS-CoV-2 were associated with progressively worsening symptoms, particularly in patients aged >65 years. This study highlights the need for preventive measures, including vaccination and revaccination of older adults with vaccines covering a broader range of S. pneumoniae serotypes.

Keywords: Respiratory Infections, Co-infection, Streptococcus pneumoniae, SARS-CoV-2, respiratory virus, Clinical Characteristics, COVID-19

Received: 21 Mar 2025; Accepted: 02 Oct 2025.

Copyright: © 2025 Trifonova, Korsun, Levterova, Pavlova, Simeonovski, Ivanova, Velikov, Voleva, Ivanov, Ivanov, Dakov, Tchervenyakova, Angelova and Christova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Ivelina Trifonova, trifonova.ivelina@abv.bg

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.